Article Text

Download PDFPDF

57 CD8+FoxP3+ cells represent early, effector T-cells and predict outcomes in patients with resectable non-small cell lung carcinoma (NSCLC) receiving neoadjuvant anti-PD-1-based therapy
  1. Emily Cohen1,
  2. Daphne Wang2,
  3. Elizabeth Engle2,
  4. Benjamin Green2,
  5. Justina Caushi2,
  6. Jiajia Zhang2,
  7. Joel Sunshine2,
  8. Sonali Uttam1,
  9. Michael Fotheringham1,
  10. Alexa Fiorante3,
  11. Nicole Espinosa1,
  12. Bhakti Pandey3,
  13. Teodora Popa1,
  14. Aleksandra Ogurtsova2,
  15. Sigfredo Soto-Diaz2,
  16. Jose Loyola2,
  17. Jeffrey Roskes2,
  18. Margaret Eminizer2,
  19. Dmitry Medvedev2,
  20. Jamie Chaft4,
  21. Julie Brahmer2,
  22. Joshua Reuss2,
  23. Patrick Forde2,
  24. Alexander Szalay2,
  25. Andrew Pardoll2,
  26. Kellie Smith2,
  27. Janis Taube2 and
  28. Tricia Cottrell1
  1. 1Queen’s University, Kingston, Canada
  2. 2Johns Hopkins University, Baltimore, MD, USA
  3. 3University of Toronto, Toronto, Canada
  4. 4Memorial Sloan-Kettering Cancer Center, New York City, USA


Background PD-1/PD-L1 pathway blockade has improved survival in patients with advanced NSCLC. Neoadjuvant (pre-operative) anti-PD-1 plus chemotherapy was also recently approved for patients with resectable stage II/III NSCLC. However, among patients receiving neoadjuvant anti-PD-1-based therapy, only 33–45% achieved a major pathologic response (MPR, ≤10% of residual viable tumor), highlighting the need for biomarkers predicting response.1,3 Based upon recent results in advanced melanoma showing that CD8+FoxP3+ cells were strongly associated with therapeutic response,4 we hypothesized that these cells would also be predictive of response in resectable NSCLC. Additionally, we performed single-cell RNA sequencing (ssRNAseq) to define the phenotype of CD8+FoxP3+ cells, given reports suggesting an immunosuppressive role.

Methods Pre-treatment formalin-fixed paraffin-embedded tumor specimens from the first-in-human clinical trial of neoadjuvant anti-PD-1 (nivolumab) +/- anti-CTLA-4 (ipilimumab) in NSCLC (NCT02259621) 1,3 were stained with a 6-marker multiplex immunofluorescence mIF panel (PD-1, PD-L1, CD8, CD163, FoxP3, and cytokeratin). Eight specimens were from patients demonstrating MPRs and 17 were from patients with non-MPRs. The densities of immune cell populations within the tumor microenvironment (TME) were analyzed using the AstroPath platform and the area under the receiver operating characteristic curve (AUC) for each possible cell phenotype was calculated for predicting MPR.4 The association for cell phenotypes with event-free survival (EFS) and overall survival (OS) was determined using the log-rank test. scRNAseq analyses were performed on freshly collected CD3+ TIL from 15 of the same NSCLC patients. T-cells were clustered by UMAP and were queried for co-expression of CD8 and FoxP3.

Results The density of CD8+FoxP3+ T-cells was significantly elevated in patients achieving MPR (AUC=0.78, p=0.014, N=25). This association was strongest in the PD-1(+) (AUC=0.83, p=0.004) and PD-L1(-) (AUC=0.81, p=0.007) subsets. The AUCs for CD8+FoxP3+ cells were stronger than any other cell phenotype labeled by this 6-plex mIF assay. Patients whose TMEs contained CD8+FoxP3+ cells (n=18) when compared to those lacking this phenotype (n=7) had improved EFS and OS (41 vs. 8 months, p=0.041; and 26 vs. 8 months, p=0.074, respectively). scRNAseq studies of the CD8+FoxP3+ T-cell subset revealed a transcriptome compatible with a highly-activated, cytotoxic phenotype (CCL5, CD8A, GZMB, NKG7, CTSW, CD8B, LINC02446, GZMK all highly expressed).

Conclusions CD8+FoxP3+ T-cells in the NSCLC TME do not represent immunosuppressive cells, as has been previously reported, but instead represent highly-potent early, effector T-cells. When detected by mIF in pre-treatment NSCLC tumor specimens, these cells associate with major pathologic response and improved survival outcomes following neoadjuvant anti-PD-1.


  1. Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., Battafarano, R. J., Velez, M. J., Rekhtman, N., Olah, Z., Naidoo, J., Marrone, K. A., Verde, F., Guo, H., Zhang, J., Caushi, J. X., … Pardoll, D. M. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med. 2018; 378, 1976–1986.

  2. Forde, P. M., Spicer, J., Lu, S., Provencio, M., Mitsudomi, T., Awad, M. M., Felip, E., Broderick, S. R., Brahmer, J. R., Swanson, S. J., Kerr, K., Wang, C., Ciuleanu, T.-E., Saylors, G. B., Tanaka, F., Ito, H., Chen, K.-N., Liberman, M., Vokes, E. E., … Girard, N. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022; 386, 1973–1985.

  3. Reuss, J. E., Anagnostou, V., Cottrell, T. R., Smith, K. N., Verde, F., Zahurak, M., Lanis, M., Murray, J. C., Chan, H. Y., McCarthy, C., Wang, D., White, J. R., Yang, S., Battafarano, R., Broderick, S., Bush, E., Brock, M., Ha, J., Jones, D., Merghoub, T., … Forde, P. M. (2020). Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. J Immunother Cancer. 2020; 8, e001282.

  4. Berry, S., Giraldo, N. A., Green, B. F., Cottrell, T. R., Stein, J. E., Engle, E. L., Xu, H., Ogurtsova, A., Roberts, C., Wang, D., Nguyen, P., Zhu, Q., Soto-Diaz, S., Loyola, J., Sander, I. B., Wong, P. F., Jessel, S., Doyle, J., Signer, D., … Taube, J. M. Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD1 blockade. Science. 2021; 372, eaba2609.

Ethics Approval This study was conducted in accordance with the Declaration of Helsinki and was performed following Johns Hopkins University IRB approval (#NA_00085595). This protocol allows for the retrieval of tissue from archives from patients who signed an informed written consent or with waiver of consent.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.